Label: PYRIDOXINE HCI injection, solution

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated February 22, 2020

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED

    100 mg/mL

  • DESCRIPTION

    Pyridoxine Hydrochloride Injection, USP is a sterile solution of pyridoxine hydrochloride in Water for Injection. Each mL contains 100 mg pyridoxine hydrochloride and 0.5% chlorobutanol anhydrous (chloral deriv.). pH adjusted with sodium hydroxide if necessary (2.0 to 3.8).

    Pyridoxine hydrochloride is a colorless or white crystal or a white crystalline powder. One gram dissolves in 5 mL of water. It is stable in air and is slowly affected by sunlight.

    The chemical name is 2-methyl-3-hydroxy-4,5-bis (hydroxymethyl) pyridine hydrochloride.

    The structural formula is:

    STRUCTURE

  • CLINICAL PHARMACOLOGY

    Natural substances that have vitamin B6 activity are pyridoxine in plants and pyridoxal or pyridoxamine in animals. All 3 are converted to pyridoxal phosphate by the enzyme pyridoxal kinase. The physiologically active forms of vitamin B6 are pyridoxal phosphate (codecarboxylase) and pyridoxamine phosphate. Riboflavin is required for the conversion of pyridoxine phosphate to pyridoxal phosphate.

    Vitamin B6 acts as a coenzyme in the metabolism of protein, carbohydrate, and fat. In protein metabolism, it participates in the decarboxylation of amino acids, conversion of tryptophan to niacin or to serotonin (5-hydroxtryptamine), deamination, and transamination and transulfuration of amino acids. In carbohydrate metabolism, it is responsible for the breakdown of glycogen to glucose-1-phosphate.

    The total adult body pool consists of 16 to 25 mg of pyridoxine. Its half-life appears to be 15 to 20 days. Vitamin B6 is degraded to 4-pyridoxic acid in the liver. This metabolite is excreted in the urine.

    The need for pyridoxine increases with the amount of protein in the diet. The tryptophan load test appears to uncover early vitamin B6 deficiency by detecting xanthinurea. The average adult minimum daily requirement is about 1.25 mg. The ‘‘Recommended Dietary Allowance’’ of the National Academy of Sciences is estimated to be as much as 2.2 mg for adults and 2.5 mg for pregnant and lactating women. The requirements are more in persons having certain genetic defects or those being treated with isonicotinic acid hydrazide (INHJ) or oral contraceptives.

  • INDICATIONS & USAGE

    Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following:

    Inadequate dietary intake.

    Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives.

    Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia.

    The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired.

  • CONTRAINDICATIONS

    A history of sensitivity to pyridoxine or to any of the ingredients in Pyridoxine Hydrochloride Injection, USP is a contraindication.

  • WARNINGS

    WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

    Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

  • PRECAUTIONS

    WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

    Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

  • ADVERSE REACTIONS

    Paresthesia, somnolence, and low serum folic acid levels have been reported.

  • DRUG ABUSE AND DEPENDENCE

    Symptoms of dependence have been noted in adults given only 200 mg daily, followed by withdrawal.

  • OVERDOSAGE

    Pyridoxine given to animals in amounts of 3 to 4 g/kg of body weight produces convulsions and death. In man, a dose of 25 mg/kg of body weight is well tolerated.

  • DOSAGE & ADMINISTRATION

    Pyridoxine Hydrochloride Injection may be administered intramuscularly or intravenously. In cases of dietary deficiency, the dosage is 10 to 20 mg daily for 3 weeks. Follow-up treatment is recommended daily for several weeks with an oral therapeutic multivitamin preparation containing 2 to 5 mg pyridoxine. Poor dietary habits should be corrected, and an adequate, well balanced diet should be prescribed.

    The vitamin B6 dependency syndrome may require a therapeutic dosage of as much as 600 mg a day and a daily intake of 30 mg for life.

    In deficiencies due to INH, the dosage is 100 mg daily for 3 weeks followed by a 30 mg maintenance dose daily.

    In poisoning caused by ingestion of more than 10 g of INH, an equal amount of pyridoxine should be given — 4 g intravenously followed by 1 g intramuscularly every 30 minutes.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  • HOW SUPPLIED

    PYRIDOXINE HCI INJECTION, USP is supplied in the following dosage forms.
    NDC 51662-1410-1
    PYRIDOXINE HCI INJECTION, USP 100mg per mL 1mL VIAL

    HF Acquisition Co LLC, DBA HealthFirst
    Mukilteo, WA 98275

    Also supplied in the following manufacture supplied dosage forms

    Pyridoxine Hydrochloride Injection, USP is supplied as:

    HOW SUPPLIED

    PROTECT FROM LIGHT.

    Use only if solution is clear and seal intact.

    Sterile.

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

  • SPL UNCLASSIFIED

    45817F

    Revised: March 2015

    LOGO

  • PRINCIPAL DISPLAY PANEL, VIAL LABEL

    VIAL PT1

    VIAL PT 2

    VIAL PT 3

  • PRINCIPAL DISPLAY PANEL, SERIALIZED LABELING

    SERIALIZED LABELING

  • INGREDIENTS AND APPEARANCE
    PYRIDOXINE HCI 
    pyridoxine hci injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51662-1410(NDC:63323-180)
    Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PYRIDOXINE HYDROCHLORIDE (UNII: 68Y4CF58BV) (PYRIDOXINE - UNII:KV2JZ1BI6Z) PYRIDOXINE HYDROCHLORIDE100 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    CHLOROBUTANOL (UNII: HM4YQM8WRC) 5 mg  in 1 mL
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:51662-1410-11 mL in 1 VIAL; Type 0: Not a Combination Product10/08/2019
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA08061810/08/2019
    Labeler - HF Acquisition Co LLC, DBA HealthFirst (045657305)
    Registrant - HF Acquisition Co LLC, DBA HealthFirst (045657305)
    Establishment
    NameAddressID/FEIBusiness Operations
    HF Acquisition Co LLC, DBA HealthFirst045657305relabel(51662-1410)